Novartis receives optimistic CHMP opinion for Kesimpta®* (ofatumumab), a self-administered remedy…
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is based on two Phase III ASCLEPIOS studies that…